{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:24:25Z","timestamp":1780316665702,"version":"3.54.1"},"reference-count":48,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cytopathology"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is a need for additional longitudinal studies with the Aptima messenger RNA human papillomavirus test (AHPV) to support the safety of extended screening intervals. RNA\u2010based extended interventional nucleic acid (REINA) provides relevant information on the clinical performance of AHPV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a longitudinal prospective analysis of 1538 participants after AHPV and liquid\u2010based cytology (LBC) co\u2010test complemented with REINA interventional protocol with a second co\u2010test 4 years after negative screening on 2000 women. Diagnostic accuracy and cumulative risks for CIN2+ up to 9 years were calculated for all test combinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sensitivity and specificity for CIN2+ were 96.9% and 88.0% for AHPV and 72.3% and 92.0% for LBC. Negative predictive value (NPV) and positive predictive value (PPV) of AHPV were 99.9% and 23.6%. The 5\u2010 and 9\u2010year risks of AHPV\u2010negative women were 0.4% and 1.0% (CIN2+) and 0.3% and 0.7% (CIN3+), a 73% and 64% lower risk than with negative LBC (<jats:italic>p<\/jats:italic>\u00a0\u2264\u00a0.002). REINA participants with an AHPV\u2010positive result at second co\u2010test after a negative AHPV in first round had a significantly lower 5\u2010year risk of CIN2+ (11.1%) than AHPV\u2010positive women with unknown HPV history (29.5%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Currently, this constitutes the longest European longitudinal study with AHPV testing in screening population. It reveals 99.9% NPV and a significant protective effect of a previous negative test 5 years after a new HPV infection. These findings support the safety of Aptima for screening intervals beyond 5 years. The risk of disease is lower 9 years after a negative AHPV test than 3 years after a negative LBC. High specificity and PPV of Aptima may benefit controlling overtreatment and colposcopy referrals.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncy.22895","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T09:44:18Z","timestamp":1724060658000},"page":"757-767","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["RNA extended interventional nucleic acid longitudinal study: Clinical performance of Aptima messenger RNA HPV testing in cervical cancer screening with a 9\u2010year follow\u2010up"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9482-622X","authenticated-orcid":false,"given":"Rosario","family":"Granados","sequence":"first","affiliation":[{"name":"Department of Pathology Hospital Universitario de Getafe  Madrid Spain"},{"name":"Universidad Europea de Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanny A.","family":"Duarte","sequence":"additional","affiliation":[{"name":"Department of Pathology Hospital Universitario de Getafe  Madrid Spain"},{"name":"Universidad Europea de Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Luj\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Pathology Hospital Universitario de Getafe  Madrid Spain"},{"name":"Universidad Europea de Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Gutierrez\u2010Pecharrom\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Pathology Hospital Universitario de Getafe  Madrid Spain"},{"name":"Universidad Europea de Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Sol\u00eds","sequence":"additional","affiliation":[{"name":"Department of Gynecology Hospital Universitario de Getafe  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Molpeceres","sequence":"additional","affiliation":[{"name":"Department of Gynecology Hospital Universitario de Getafe  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Bajo","sequence":"additional","affiliation":[{"name":"Department of Pathology Hospital Universitario de Getafe  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Palencia","sequence":"additional","affiliation":[{"name":"Department of Gynecology Hospital Universitario de Getafe  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Department of Gynecology Hospital Universitario de Getafe  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"1","volume-title":"European guidelines for quality assurance in cervical cancer screening","author":"Ronco G","year":"2015"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21628"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62218-7"},{"key":"e_1_2_8_4_2","unstructured":"doi:10.1016\/s0140\u20106736(13)62218\u20107"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(09)70360\u20102"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd008587.pub2"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.22"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21875"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.2005.203"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.86"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1822"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4924"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta18230"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta23280"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.03558\u201014"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25726"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01517\u201013"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1309\/ajcphvd7mip3fyvv"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2018.09.004"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01177\u201018"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31819"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34685"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055\u20109965.epi\u201020\u20101177"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32695"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.04.031"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj\u20102021\u2010068776"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(22)00294\u20107"},{"key":"e_1_2_8_28_1","first-page":"1","article-title":"HPV testing on cervical specimens: Which assays can be used in primary screening? In: European Society of Gynaecological Oncology (ESGO)","author":"Arbyn M","year":"2023","journal-title":"Texbook of Gynaecological Oncology"},{"key":"e_1_2_8_29_1","unstructured":"Prevenci\u00f3n del c\u00e1ncer de cuello de \u00fatero Oncogu\u00eda SEGO:"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/dc.23821"},{"key":"e_1_2_8_31_1","unstructured":"Torn\u00e9A delPinoM And\u00eda et\u00a0al.AEPCC\u2010Gu\u00eda: PREVENCI\u00d3N SECUNDARIA DEL CANCER DE CUELLO DEL \u00daTERO 2022.CONDUCTA CL\u00cdNICA ANTE RESULTADOS ANORMALES DE LAS PRUEBAS DE CRIBADO.https:\/\/www.aepcc.org\/wp\u2010content\/uploads\/2022\/05\/AEPCC\u2010Guia_Prevencion\u2010cancer\u2010cervix_2022_v05.pdf"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/lgt.0000000000000529"},{"key":"e_1_2_8_33_1","unstructured":"European Cancer Information System. Accessed on April 19 2024.https:\/\/ecis.jrc.ec.europa.eu."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147326"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010016\u20102961\u20102"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimce.2022.08.001"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29191"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2023.200268"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.10.027"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.01.002"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1159\/000358246"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/lgt.0000000000000143"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102019\u2010031303"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2021.101448"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12905\u2010021\u201001310\u20108"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12905\u2010023\u201002219\u20100"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000029530"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2021.05.038"}],"container-title":["Cancer Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncy.22895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:46:05Z","timestamp":1760280365000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncy.22895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/cncy.22895"],"URL":"https:\/\/doi.org\/10.1002\/cncy.22895","archive":["Portico"],"relation":{},"ISSN":["1934-662X","1934-6638"],"issn-type":[{"value":"1934-662X","type":"print"},{"value":"1934-6638","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"2024-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}